Future Trial and Dissemination
Cross-source consensus on Future Trial and Dissemination from 1 sources and 4 claims.
1 sources · 4 claims
Comparisons
Other
Other
Highlighted claims
- The planned full trial will compare My Story and Me plus treatment as usual with treatment as usual alone. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals
- Progression to a full cluster RCT will not be recommended if recruitment implies more than 50 sites would be needed. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals
- Progression will not be recommended if two or more progression criteria are rated red. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals
- Dissemination will include open-access publications, lived-experience summaries, conference presentations, and a policy briefing. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals